Geron Corporation (GERNW)

Market Cap	1.82B
Revenue (ttm)	29.48M
Net Income (ttm)	-201.19M
Shares Out	n/a
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,100
Average Volume	1,900
Open	0.361
Previous Close	0.400
Day's Range	0.263 - 0.413
52-Week Range	n/a
Beta	n/a
RSI	27.66
Earnings Date	Mar 7, 2025

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 229
• Stock Exchange: OTCMKTS
• Ticker Symbol: GERNW